SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608851515/en/
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
About SOLVE FSHD
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
About Modalis Therapeutics Corporation
Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608851515/en/
CONTACT: SOLVE FSHD
Alexandra Grant, House of Wilson
[email protected]
Modalis Therapeutics Corporation
Corporate Planning Department
[email protected]
KEYWORD: MASSACHUSETTS NORTH AMERICA UNITED STATES ASIA PACIFIC JAPAN CANADA
INDUSTRY KEYWORD: RESEARCH GENETICS HEALTH TECHNOLOGY PHILANTHROPY BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH OTHER PHILANTHROPY SCIENCE
SOURCE: SOLVE FSHD
Copyright Business Wire 2025.
PUB: 06/08/2025 07:30 PM/DISC: 06/08/2025 07:31 PM
http://www.businesswire.com/news/home/20250608851515/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
No-swimming advisories at 8 Metro Vancouver beaches
If you're planning to take a swim in Metro Vancouver, better check with Vancouver Coastal Health. Several beaches have been put under advisories because of elevated E. coli levels. Johna Baylon hit the west end and Stanley Park to find out how beachgoers are faring.
Wall Street Journal
an hour ago
- Wall Street Journal
Japan Inflation Eases, But BOJ Still Faces Policy Challenges
TOKYO—A slight easing in Japan's consumer inflation is welcome news for the central bank, but stubbornly high food prices will be of concern for policymakers whose hands remain tied by tariffs. Core consumer prices, which excludes volatile fresh food prices, rose 3.3% from a year earlier in June, government data showed Friday. That compared with May's 3.7% rise, and matched the forecast in a poll of economists by data provider Quick.
Yahoo
an hour ago
- Yahoo
Clara Technologies Announces Free Trial for Sales Buddi in Response to Positive Initial Feedback
Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - Clara Technologies Corp. (CSE: CLTE) (FSE: 4BH) (WKN: A3E4MS) ("Clara" or the "Company"), an innovator in enterprise-level AI solutions, is pleased to announce a strategic update to its flagship product Sales Buddi, a mobile-first AI sales coaching app now available on the Apple App Store and Google Play. Following strong early adoption and positive user feedback from its launch, including approximately 500 downloads within the first few weeks of launch, despite no formal marketing initiatives, Clara intends to implement a 5-day free trial period for new users beginning Monday, July 21, 2025. This initiative is designed to increase accessibility and allow prospective users to experience the platform's full value prior to subscribing. As part of this growth-focused strategy, Clara will also reduce the app's monthly subscription price from $50 to $25 USD, effective on the same date. The revised pricing is designed to support broader adoption among individual sales professionals and accelerate community growth. These decisions reflect the Company's long-term focus on recurring revenue through software-as-a-service (SaaS) subscriptions and building a loyal user base within the Sales Buddi platform. About Sales Buddi Sales Buddi is a mobile AI sales coach designed to support sales professionals with real-time strategy, mindset coaching, and post-meeting follow-up planning. Users complete an onboarding process to identify their sales personality, which helps customize their experience within the app. Once active, the platform provides actionable coaching, follow-up prompts, and motivational support tailored to each user's style. For more information, visit About Clara Technologies Corp Clara Technologies Corp is a forward-thinking enterprise technology company developing AI tools to optimize business performance. Its flagship platform Sales Buddi is designed to transform how companies approach sales training, operational intelligence, and employee development. For more information about Clara Technologies Corp and Sales Buddi, visit On Behalf of the Board of Directors Gerald TrittDirector (778) 561-3607ir@ Forward-Looking Statements This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than statements of historical fact, included herein are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and other factors include, among others, statements as to the anticipated business plans and timing of future activities of the Company, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company's operations and the Company's limited operating history. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this press release except as otherwise required by law. The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
